Know Cancer

forgot password

A Phase I Study of Triapine® in Combination With Radiation Therapy in Locally Advanced Pancreas Cancer

Phase 1
18 Years
Open (Enrolling)
Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer

Thank you

Trial Information

A Phase I Study of Triapine® in Combination With Radiation Therapy in Locally Advanced Pancreas Cancer


I. To determine the maximal tolerable dose (MTD) of 3-AP administered in combination with
radiation therapy (XRT) in patients with locally advanced pancreatic carcinomas.


I. To document the therapeutic response of this combination in patients with locally
advanced pancreatic carcinomas.

II. To establish radiographic correlates using secretin stimulated magnetic resonance
cholangiopancreatography (MRCP) and dynamic contrast enhanced magnetic resonance imaging

III. To measure deoxycytidine triphosphate (dCTP) levels in peripheral blood mononuclear
cells (PBMCs)before and after treatment at specified times and try to correlate findings to
activity and toxicity of triapine.

OUTLINE: This is a dose-escalation study of 3-AP (Triapine®). Patients undergo radiotherapy
once daily, 5 days a week, for approximately 5½ weeks (a total of 28 fractions).

Patients also receive 3-AP (Triapine®) IV over 2 hours 3 days a week every other week for 5½
weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine®) until the maximum
tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which
at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients
are treated at the MTD. After completion of study treatment, patients are followed monthly
for 1 year.

Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the pancreas

- Unresectable nonmetastatic (stage III) disease

- ECOG performance status 0-2

- Life expectancy > 12 weeks

- WBC ≥ 3,000/mm^3

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Total bilirubin ≤ 2 times upper limit of normal (ULN)

- AST/ALT ≤ 3 times ULN

- Creatinine normal ORcreatinine clearance ≥ 60 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception prior to and during study treatment

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to 3-AP (Triapine®) or other agents used in study

- No known glucose-6-phosphate dehydrogenase (G6PD) deficiency

- No uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would complicate compliance
with study treatment

- No pulmonary disease (i.e., dyspnea at rest, requiring supplemental oxygen, or
baseline oxygen saturation < 92%)

- No prior chemotherapy or radiotherapy

- No concurrent antiretroviral therapy for HIV-positive patients

- No other concurrent investigational agents

- No other concurrent anticancer agents or therapies

Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

MTD as assessed by the number of patients with dose-limiting toxicity (DLT)

Outcome Description:

MTD will be the dose at which 1 or fewer patients (less than or equal to 1/6) experiences a DLT during the treatment cycle with the next higher dose having at least 2/3 or 2/6 patients experiencing DLT. DLT will be defined as greater than or equal to Grade 3 non-hematologic or greater than or equal to Grade 4 hematologic adverse event with the following exceptions: greater than or equal to Grade 3 nausea and greater than or equal to Grade 3 vomiting that improves with antiemetic therapy greater than or equal to Grade 3 diarrhea that improves with Lomotil.

Outcome Time Frame:

Observed clinically for 3-4 hours after each 3-AP infusion during the first week of treatment

Safety Issue:


Principal Investigator

Tanios Bekaii-Saab

Investigator Role:

Principal Investigator

Investigator Affiliation:

Ohio State University


United States: Food and Drug Administration

Study ID:




Start Date:

December 2006

Completion Date:

Related Keywords:

  • Adenocarcinoma of the Pancreas
  • Stage III Pancreatic Cancer
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Pancreatic Neoplasms



Ohio State University Medical Center Columbus, Ohio  43210